ULTRAGENYX PHARMACEUTICAL INC. Contractual Obligation, to be Paid, Year Four
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Contractual Obligation, to be Paid, Year Four of $62.00 thousand as of 2016-12-31, per its 10-K filed 2017-02-17.
Discontinued › Notes › Commitment and Contingencies › Contractual Obligation, Fiscal Year Maturity › Contractual Obligation, to be Paid, Year Four and Five
us-gaap:ContractualObligationDueInFourthYear · last filed 2017-02-17
- 2016-12-31: Contractual Obligation, to be Paid, Year Four $62.00K.
- 2015-12-31: Contractual Obligation, to be Paid, Year Four $83.00K.
| Period end | Contractual Obligation, to be Paid, Year Four |
|---|---|
| 2016-12-31 | $62.00K 10-K · filed 2017-02-17 |
| 2015-12-31 | $83.00K 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |